Drilldown: Medicines

None (2) · Acyclovir (1)

Ajovy (1) · Emgality (1) · Zovirax (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Anti-herpesvirus_agents|Anti-herpesvirus agent]] (1) · [[:Category:Antivirals|Antiviral]] (1) · [[:Category:Nucleoside_analogs|Nucleoside analog]] (1)

None (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000909-QINU`"', '"`UNIQ--vote-0000090A-QINU`"', '"`UNIQ--vote-0000090B-QINU`"', '"`UNIQ--vote-0000090C-QINU`"', '"`UNIQ--vote-0000090D-QINU`"', '"`UNIQ--vote-0000090E-QINU`"' (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

120 mg/mL prefilled syringe or autoinjector (1) · 200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical) (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 675 mg/quarter (1) · Indication-specific; high-dose IV regimens for encephalitis or disseminated disease (1)

IV (1) · Oral (1) · Subcutaneous (2) · topical (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

8 hours per oral dose (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

~27 days (1) · ~3 hours; significantly prolonged in renal impairment'"`UNIQ--ref-0000090F-QINU`"' (1) · ~31 days (1)

Not formally established (1) · Not formally established (high SC) (1) · ~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' (1)

Limited data; avoid (2) · Widely used in pregnancy for HSV/VZV indications; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (1)